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Abstract
Myocardial infarction (MI), commonly known as a heart attack, is the irreparable
necrosis of the cardiac tissue due to sustained ischemia. MI may lead to heart failure. Despite
advances in treatments, the number of patients with heart failure is increasing. Engineered heart
tissue, EHT, could offer an innovative approach to treating areas of infarcted cardiac tissue.
Ideally, EHT should integrate and function with the native heart without causing a higher risk for
complications. The purpose of this study is to design a system to identify potentially
arrhythmogenic sites in EHT. Specifically, an electrode array complete with DAQ system and
data analysis program was developed to record electrical propagation and interpret conduction
velocity (CV) speeds to identify areas of slow conduction. This system has the ability to analyze
the activation times, calculate CV vector fields, and identify areas within the mapping window
that display slow CV speeds and are considered arrhythmic-prone.
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I. Introduction
A.

Myocardial Infarction
Myocardial infarction (MI), or more commonly known as a heart attack, is the irreparable

necrosis of the cardiac tissue due to sustained ischemia. This lack of blood flow to an area of the
heart can arise from many different sources such as coronary heart disease (CHD) and/or blood
clots that block an artery to the heart [1]. MI is a life threatening condition that if not treated
correctly could lead to heart failure. Approximately 1.5 million cases of MI occur annually in the
US alone. The Global Burden of Disease study found that in 2010 an estimated 29.6% of deaths
worldwide were caused by cardiovascular disease. In 2011, an MI was one of the top five most
expensive inpatient hospitalizations in the US [2]. Currently, ischemic heart disease is the
leading cause of death worldwide. According to the American Heart Association, about every 43
seconds, someone in the United States has a myocardial infarction [3].
An MI may lead to heart failure, arrhythmia, or cardiac arrest. Risk factors include, but
are not limited to, diabetes, smoking, lack of exercise, obesity, high blood pressure, and high
blood cholesterol. The most common symptoms of MI include chest discomfort, upper body pain
that may spread beyond the chest to the arms, shoulders, back and neck, stomach pain that may
mimic heartburn, shortness of breath, anxiety, dizziness, sweating, nausea and vomiting. Most
heart attacks typically begin as discomfort rather than immediate pain and begin to increase in
severity over the course of several minutes [6]. In 2005, 92% of respondents recognized chest
pains as a symptom of heart attack and only 27% were aware of all of the major warning signs
[7].

B.

Post Myocardial Infarction Interventions
Identification and treatment after MI is critical for a successful recovery of the patient.

Immediate intervention for this circumstance may include aspirin, diuretic, beta-blockers, other
antiarrhythmic drugs, as well as the use of and electrical defibrillator for cases of severe
arrhythmic episodes [1]. Depending on the extent of tissue damage, surgical procedures, such as
RF ablation, or the use of an implantable device, such as a defibrillator or pacemaker, may be
used [8].
Certain medications, in particular anticoagulants, are able to prevent blood clotting. This
decreases both formation of new blood clots and continued growth of existing clots. These drugs
have the ability to stop or decrease growth rate of existing blood clots, not break them down. The
purpose of this particular treatment is to prevent the blood clots from moving into a location that
would prevent oxygen to an area of the cardiac tissue. In order to decrease potential fluid
accumulation, diuretic drugs are administered. Diuretics enable the body to reduce excess fluids
and sodium through urination. This helps reduce blood pressure and reduce the heart’s workload.
This also prevents build up of fluids in the lungs and other parts of the body [9]. Beta-blockers,
or beta-adrenergic blocking agents, are medications that help reduce blood pressure by inhibiting
the effects of epinephrine. When beta-blockers are administered, the heart beats slower and with
less force, thereby reducing blood pressure, chest pain, and the chance of mild arrhythmias. They
are also able to help blood vessels relax which improves blood flow [10].
Depending upon the severity of the MI, angioplasty may be necessary. Angioplasty, also
know as percutaneous coronary intervention, is used to physically widen a blood vessel where
blood flow is restricted or blocked. This is accomplished by inserting a catheter with a
uninflated balloon typically through the femoral or radial artery to gain access to the vascular
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system. Once placed at the affected site, the balloon is expanded to enlarge the vessel and
restore proper blood flow. Often times angioplasty is combined with the permanent placement
of a stent, a small wired mesh tube, which helps keep the artery open [11].
There are more invasive procedures, including coronary bypass grafting, commonly
referred to as bypass surgery. The aim is to divert the flow of blood around an artery that may be
partially or completely blocked to improve blood flow to the cardiac tissue. For this procedure, a
healthy blood vessel is taken from the patient’s body, generally from the leg or arm. One end is
connected to the coronary artery in the heart while the other is connected to the area where there
is impaired blood flow so that oxygenated blood is able to bypass the blocked area [12,13].
In cases of severe MI, where normal pacing in the heart is altered leading to arrhythmia,
the implantation of a pacemaker or implantable cardiac defibrillator, ICD, is necessary [14].
ICDs are small, battery powered devices that are implanted just under the skin. Leads from the
subcutaneous device are inserted tranvenously and advanced into the cardiac tissue. ICDs
operate by analyzing the electrical activity in the heart and deliver electrical shocks to restore
normal rhythm if abnormal activity is detected [15].

C.

Arrhythmia
A healthy heart’s contraction cadence is essential for the efficient circulation of blood

throughout the body. The heart has four chambers, the top two are called the atria, and the
bottom two are called the ventricles. The atria, when relaxed, receive blood from the body and
contract to move blood to the ventricles. After filling, the ventricles will then contract and push
the blood to the body.
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Contractions of the different chambers of the heart are controlled by the propagation of
electrical signals called action potentials. The action potential wavefront in normal sinus rhythm
propagates from the SA node, through the atria to the AV node, finally moving through the
bundle branches and Purkinje fibers into the ventricles allowing for efficient contraction timing
of the chambers in the heart and for effective blood flow. A cardiac arrhythmia is an irregularity
with the rate or rhythm of the heartbeat. This abnormality can cause the heart to beat too slow,
too fast, or with an irregular rhythm [16]. The electrical signals that would normally propagate
through the cardiac tissue in a coordinated, timely manner now move chaotically through the
tissue, causing irregular electrical activity in areas, and ill-timed contraction of the of the cardiac
muscle. Spiral waves, rotors, or re-entrant circuits have become widely accepted as origins for
many cardiac arrhythmias [17]-[20]. Connections between particular regions of the tissue may
lead to the “current sink” or “current source” manifestation. Current sinks/sources occur when
the excitability of a tissue region delivering the depolarization of the current, the source, is not
equal to the excitability of the tissue region receiving the current, the sink [21] (Fig. 1). These
electrical waves continually stimulate the tissue at a higher rate than normal sinus rate, inhibiting
normal conduction in the tissue that can lead to arrhythmia [22]. Although slow conduction
velocity (CV) may not be the only contributor to reentry in an infarcted area of the tissue, it does
reduce the length of reentrant circuits and increases the chances for reentry [22].
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Fig. 1. This illustration from a fibrillation review by Schotten et al. [20] illustrates the direction
of propagation for areas of cardiac tissue with varying conduction velocity (CV) speeds. It is
important to understand that the electrical propagation of the heart depends on the balance
between the “source” and “sink” of the depolarizing current. In a convex wavefront, leading
cells activate more cells in front of it resulting in a small current source, a lower CV, and a
greater potential for a reentrant circuit to occur. In concave wavefronts, many cells contribute to
the activation of fewer downstream cells increasing CV [20].
D.

Conduction Velocity
Action potential conduction is a product of complex interactions between cellular

electrical activity, cardiac tissue structure, and electrical communication between cells. The CV
of an action potential is vital in the ability for the heart to control the timing of contractions of
the different chambers. The source-sink relationship, which represents the interactions between
membrane elements (source) and tissue structure elements (sink), is important to consider when
discussing CV and its significance in arrhythmia. Slowed CV in particular regions of the cardiac
tissue is a marker of an underlying issue. There are multiple mechanisms associated with
conduction slowing. These mechanisms include ischemia, scar tissue formation, cell shape, cell
size, gap junction expression, and gap junction distribution [23]. These physical properties all
have the ability to introduce an arrhythmia, making CV an important marker to determine
arrhythmic prone sites in cardiac tissue.
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E.

Engineered Heart Tissue
Despite advances in both pharmacological and surgical treatments the number of patients

with MI related deaths have not declined [24]. A marked reduction in quality of life and a high
mortality rate due to heart failure in patients in not only the US but globally has stimulated the
need for additional treatment strategies [25]. Engineered heart tissue, EHT, could offer an
innovative approach to treating areas of infarcted cardiac tissue.
Scientists have developed patches of myocyte-seeded scaffolds that might be utilized to
replace diseased areas of a living heart [26]. An EHT should integrate and function with the
native heart both mechanically and electrically. The complete EHT will be contractile,
mechanically durable/flexible, able to vascularize quickly upon implantation, and assimilate
electrically into local cardiac tissue. Unfortunately, an EHT that encompasses all of these ideal
characteristics has not yet been developed [27]. In essence, the cardiac tissue-engineering field is
attempting to be able to replace diseased myocardium with prefabricated EHT. Multiple groups
have been able to construct 3D EHT from neonatal rat heart cells in vitro [25]. The immediate
issue that must be addressed is the functional properties of the EHT (mechanical function,
vascular adaptation, electrical function, etc.) and if the EHT is a viable long term solution for
diseased cardiac tissue. The result of the EHT’s integration should result in improved cardiac
function without inducing a higher risk for complications. The optimal EHT should have the
ability to assimilate with the surrounding healthy tissue and maintain all essential cardiac tissue
function [26].
The primary concerns are the ability of the EHT patches to improve function of the
damaged cardiac tissue area and not serves as a catalyst for an arrhythmogenic site. If the EHT
patch were conducting the action potentials slower than that of the surrounding healthy tissue,
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then there would be an increased risk for developing an arrhythmia. Therefore, a valuable
electrical characteristic to establish in the EHT is conduction velocity.

F.

Current cardiac tissue characterization techniques
Cardiac mapping is a general term that includes different types of mapping techniques.

These various techniques can include electrode arrays or sophisticated optical mapping
techniques using voltage-sensitive dye and imaging systems with high temporal and spatial
resolutions [28]. Electrophysiological studies of cardiac tissue often use isolated ex vivo
characterization techniques that allow for controlled environments without the potential bodily
interference that may compensate for certain situations in in vitro models; like the nervous
system increasing heart rate via epinephrine [29].
Extracellular electrograms are considered the hallmark of invasive cardiac
electrophysiology and provide essential information about the electrical activity in the
underlying myocardium. An extracellular electrogram may be recorded from an electrode array
in direct contact with cardiac tissue. The electrograms are created by the depolarization of the
cardiomyocytes that generate transmembrane currents in the extracellular space. Under
pathological conditions, however, electrograms may consist of unusual components that are
attributed to abnormal CV [30]. In the case of in vitro analysis, a system to maintain
physiologically relevant environment where pH and temperature are controlled is needed.
Dulbecco’s Modified Eagle Medium (DMEM, balanced salt solution) mixed with CO2 has been
previously used in order to provide a suitable environment as well as tissue viability [29, 31].
This bath system can also be used in-vivo and may be used to characterize pieces of cardiac
tissue as well as EHT.
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A successful ex vivo cardiac mapping experiment hinges upon two primary targets:
1.

Tissue viability must be maintained in order to give relevant data. Perfusion technique,
nutritional medium, O2-CO2 interaction to maintain pH balance, and temperature control
can be used to ensure normal tissue function.

2.

Comparative analysis of current and past electrical conduction in tissue sample results to
determine effectiveness of environment control.
Previous work at University of Memphis has produced an inexpensive and simple tissue
bath system to maintain a physiologically relevant environment for isolated ex vivo cardiac
tissues [29], a data acquisition system to record extracellular electrograms, and data analysis
software to determine activation time of the tissue [32]. Activation time data was then
processed offline to give CV characteristics of the tissue [29].

G.

Objectives
The overall objective of this study is to develop a cardiac mapping system to reliably

determine activation time sequences in cardiac tissue samples. From these calculations, we
determine CV for the tissue sample and translate that information into conduction characteristics
and characterize areas of the cardiac tissue sample that display abnormal or arrhythmic prone
traits.
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Project objectives include:
1. Construct an inexpensive and simple electrode array that can be used to interact
with cardiac tissue samples.
2. Develop a data acquisition and analysis system that can be used to determine
activation times of the tissue, calculate CV, and identify and flag areas of the
tissue that display abnormal conduction tendencies.
3. Perform experiments using porcine cardiac samples to evaluate the performance
of our system on the response of the tissue to current stimuli.
4. Expand and update the previous methods in the lab of cardiac tissue
characterization.
The method of cardiac tissue analysis via electrode mapping array along with an analysis
program to determine regions of abnormal conduction in semi-automated will serve as a valuable
tool to identify arrhythmic prone regions within the tissue sample. This method may have the
ability to be expanded or refined to act as an EHT screening device.
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II. Methods
The methods followed in this project were from a recognized standard from researchers
and scientists in cardiac mapping [31]. These practices include determining stimulation/response
threshold values, activation time calculations, as well as CV characteristics. Initial methods
directly follow work previously performed in the lab by Villa [29].

A.

Tissue bath development
A rectangular acrylic chamber used in previous studies was used as the tissue bath system

chamber. Tissue clamps anchored to the bottom of the chamber hold the tissue samples in place
during stimulation and recording. Physiological temperature was maintained by setting the
chamber in a water bath continually heated via a ceramic hotplate. The chamber was filled with
DMEM (Lonza BioWhittaker™ Dulbecco's Modified Eagle's Medium from Fisher Scientific) to
a level that completely submerged the tissue by 1-2 mm [29,31]. The DMEM was continuously
circulated at 120 ml/min using a Masterflex tubing pump. Temperature was controlled inside the
chamber at 37±0.5 °C by using the hotplate with controller (IKA® C-MAG HP7 and
IKATRON® ETS-D5, respectively); water level inside the metal pan was filled to surpass the
level of the medium within the chamber. Water must be monitored and added throughout the trial
as evaporation occurs during the experiment. The pH was maintained between 7.32±0.04 by
bubbling in CO2 using an automatic pH controller (BL931700, Harvard Apparatus).
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Fig. 2. Cross-sectional view of the constructed tissue bath system to maintain appropriate
physiological conditions for cardiac tissue samples [29].
B.

Tissue sample preparation
Our system’s ability to maintain appropriate physiological conditions was tested using

porcine cardiac tissue. Porcine samples were acquired from Dr. Randal Buddington, Professor,
School of Health Studies, University of Memphis. Piglet age varied from 5 weeks to 13 weeks.
Piglets were euthanized using a cardiac and respiratory knockout, SomnaSol Euthanasia solution.
The freshly removed heart was immediately placed on ice and transported, in under ten
minutes, to the lab for analysis. The heart was rinsed in warmed saline to help prevent potential
blood clot formation that may interfere with electrical stimuli and data recording. Dissection
involved removing both atria as well as the right ventricle. The left ventricle was cut through the
interventricular wall to allow the tissue to lay flat with the epicardium of the left ventricle facing
11

upward and paced into the tissue bath system, completely submerged by the DMEM solution,
secured by the tissue clamps, and allowed to settle for 5-7 minutes to stabilize. During this time,
the tissue was continuously evaluated for viability; this assessment was based on color, texture,
and firmness of the tissue. Experiment was ended when the tissue became hard or if no electrical
response was observed following stimulation.

C.

Electrical characterization of the cardiac tissue
Mapping system: The mapping system we developed consists of an array of 11x11

Ag/AgCl coated copper electrodes (Fig. 3 A), and a reference electrode (Fig. 3 B) connected to a
data acquisition system with LabVIEW interface. Each tissue sample was stimulated, via current
stimulation program developed in LabVIEW and driven through a current Output Module
designed for CompacDAQ (NI 9265; 4-Channel, 0 mA to 20 mA, 16-Bit Analog Output Module;
National Instruments, Austin, TX.). The system contains 3 modules (NI 9205; 32-Channel, ±200
mV to ±10 V, 16-Bit Analog Input Module; National Instruments, Austin, TX.) that use 27
channels for amplification and filtration each which produce 81 total electrical channels for data
acquisition. Electrograms, in the form of analog signals, recorded from each of the electrodes
within the 9x9-recording matrix are transferred individually through a Compact DAQ (NI-cDAQ
9174; 16-Bit Analog NI CompactDAQ; National Instruments, Austin, TX.) to a Dell Optiplex
GX620 computer where data is collected and displayed as individual electrograms. These
electrograms are then processed through a programmed LabVIEW interface where twodimensional electrical characterization analysis is performed.
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A.

B.

Fig. 3. (A) Electrode array: 9x9 recording electrode matrix, 0.254 mm electrode diameter, 0.61
mm separation between electrodes. (B) Reference electrode (28 mm x 34 mm) was constructed
from silver foil and electroplated (Ag/AgCl) [29].
Stimulation and mapping protocol: The protocol for stimulation and mapping followed
previous efforts in the lab by Villa [29]. The pacing threshold was found by delivering a square
wave stimulus, 3 ms pulse width, at 1 Hz for 5 s, from a line of electrodes that borders one side
of the electrode array. The initial amplitude for the stimulus started at 0.5 mA and was increased
by 0.1 mA until tissue activation was achieved (Fig. 4 and Fig. 5). Once a pacing threshold was
verified, the tissue samples were stimulated at 1.5 times the pacing threshold value and
electrograms were recorded for episodes of 20 s. After successful tissue activation and recording,
temperature and pH levels were recorded to continually maintain applicable physiological
conditions.
Fig. 4 A-C were obtained from previous experiments [29] where tissue activation was
achieved following current input. Due to the limited porcine samples tissue activation was not
achieved in our experiments. Fig. 5 shows results from our efforts in the lab. Although tissue
activation was not achieved the experiment, we successfully mapped electrical potential changes
in all 81 of our mapping electrodes as well as successfully developed a current stimulation
module that allowed us to manipulate the pulse width and amplitude of current input.
13

A
)

B)

C)

Fig. 4. (A) Electrogram recording from a porcine tissue sample at an electrode 8 mm (vertical
distance) from the stimulation site from which a 0.7 mA stimulus was delivered. The large
negative deflection is the stimulus artifact. (B) An active response was achieved after the
stimulus artifact at the same electrode location as Fig. 3. The stimulus delivered was 0.9 mA, the
activation threshold for this tissue sample. (C) The first derivative of the signal in (B) is shown.
The first large negative/positive deflection corresponds to the stimulus artifact. The nadir of the
second large negative deflection corresponds to the activation time for this response.
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A
)

B)

Fig. 5. (A) View of the user interface for all 81 mapping electrodes for the current LabVIEW
program. The stimulus artifact is seen in all 81 of the mapping electrodes. There is no large
deflection detected following the stimulation suggesting tissue activation was not achieved.
Single (B) electrode view from (A). The LabVIEW program allows the user to individually
monitor a single electrode. Again, the stimulus artifact is seen in the single electrode. There is a
small deflection following the stimulus artifact. However, the amplitude as well as the duration
of the deflection (>200 ms) suggests that it is not tissue activation.
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D.

Data Analysis
Electrograms for each of the individual electrodes were evaluated to determine if the

underlying tissue was activated. The activation time for each electrode was found as the
maximum negative value of the first derivative (dV/dt) from its respective electrogram during
the pacing cycle (Fig. 4) [33]. An electrode was considered active if the maximum negative value
was less than -0.5 V/s [34]. Pacing episodes data was analyzed for electrical wavefronts, and
episodes that displayed an electrical wavefront across entire electrode array were selected for
data analysis. These data sets were evaluated using a LabVIEW VI (Virtual Instrument)
developed to analyze the electrode matrix data. The programed LabVIEW VI reviews the spatial
distributions of activation times. If the activation time difference of a given electrode was greater
than two standard deviations compared to the window of 3 to 6 surrounding electrodes, the value
was considered an outlier and the value is eliminated. A MATLAB script was developed to
import data from the LabVIEW VI that also displays relative activation times of each individual
electrode as a contour plot, calculates conduction velocity speed and direction, and identify areas
of the tissue that exhibit slow CV speeds that are considered arrhythmic prone.
Conduction velocity describes the local magnitude and direction of electrical propagation
activity in the heart tissue and may fluctuate depending on tissue properties, fiber orientation,
gap junction placement, and previous activity, all of which have the ability to change over time
and significantly differ depending on location within the tissue [35]. The magnitude of
conduction velocity was measured by determining the direction of propagation and calculating
the distance a particular wave front travels over the difference in time of activation between two
electrode points. After tissue activation times were determined for the individual electrodes, CV
vectors representing the speed and direction of electrical propagation were calculated using a
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MATLAB script. This MATLAB script uses previous methods provided by Bayly et al. [36]. The
method uses spatial windows that are defined as six or more adjacent electrodes that have
recorded activation times. The spatial windows are then projected as velocity vectors from the
partial derivatives of fitted polynomials T(x,y) to a data set of spatial activation points (x,y,t)
using a least squares fitting procedure, where x and y are locational characteristics of the
electrodes within the electrode matrix and t is the time the particular electrode was activated
based on the criteria previously mentioned. An activation time contour plot and CV vector plot is
displayed to allow for a quick analysis of the overall electrical propagation. The conduction
velocity is then plotted into an intensity graph where speeds are represented as normal
conduction speed (green), or slow conduction speed/arrhythmic prone site (red). Abnormal CV
speed that is flagged using red is under 0.08 m/s. Areas that display CV speeds slower that 0.08
m/s are highly susceptible to reentrant circuits, a major cause of arrhythmia [40]. This allows for
real time analysis and determines if/where an arrhythmic prone site is located within the
electrode array portion of the cardiac tissue. The mean conduction speed for each pacing episode
was calculated as an average of the magnitude of each velocity vector within the episode.
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III. Results
This research investigates the capability of cardiac mapping system in two manners. First,
the electrode array must be validated; the electrode array must drive a desired current through a
line of electrodes as well as determine electric potential changes in individual electrodes to map
electrical propagation on the surface of the tissue substrate. Second is the ability to determine
activation times in each of the 81 mapping electrodes, calculate conduction velocities, and
identify areas within the 9x9 mapping region that present arrhythmic prone CV speeds.
Preliminary testing in saline solution procedure and results are shown in Appendix D.

A.

Activation Thresholds
Activation thresholds are defined as the minimum stimulus amplitude required achieving

a response from the tissue sample. The VI built in LabVIEW allows the user to manipulate both
the amplitude, pulse width, duration of stimulus, and pulse interval of the current to create the
desired current waveform. Amplitude for current in all five porcine experiments began with a
current of 0.65 mA and a pulse width of 3 ms and was increased by 0.1 mA until 1.4 mA
amplitude was reached. Activation thresholds for previous experiments performed by Villa [29]
were found at 0.88±0.09 mA; however, due to the limited number of porcine samples available
activation thresholds were not achieved.

B.

Activation Time Identification and Conduction Velocity Analysis
Activation times for individual electrodes are necessary in determining both electrical

wavefronts and conduction velocity. Previously, relative activation times were determined
through extensive post processing by the user. Now, the LabVIEW VI that has been developed is
18

able to determine relative activation times of individual electrodes immediately following a
pacing episode. This is achieved by a windowing mechanism that allows the investigator to
select epochs of raw data to be analyzed and processed. Once a particular set of data is found and
processed it is converted into a set of data for each electrode (X electrode position, Y Electrode
position, Activation time). These values are then recorded and manually exported as an Excel
spreadsheet. Next, the Excel spreadsheet is imported into a MATLAB program that displays
activation time contour plots. Because tissue activation was not achieved in porcine experiments
previous data from the Villa experiments were used to verify activation time determination
method. The activation times are plotted as a function of space (mm) of the 9x9 electrode
recording region. Fig. 6 shows a contour map for activation times for two sets of former porcine
data. The activation contour maps show the distribution of activation times at regions of the
cardiac tissue. We expected and observed increased activation times as the electrical wavefront
propagated from the line of stimulation electrodes at the bottom of the display.
Conduction velocity vectors, as previously mentioned, are computed using the developed
MATLAB program employing the method described by Bayly et al. [36]. Qualitative inspection
of the velocity vector field shows an overall direction of flow from the line of stimulating
electrodes. Fig. 6B shows the velocity vector field.
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A)

B)

Fig 6. (A) Contour plot of activation times (ms) of the 9x9 mapping portion of the electrode
array. Stimulation occurred from the bottom of the electrode array. As expected the activation
times increase as the wavefront propagates away from the line of stimulation electrodes at the
bottom edge of the array. The contour plot is shown as an 8x8 square due to the polynomial
fitting window used to interpolate activation times between electrodes. B) Velocity vector field
plot of (A) activation time data. The electrical propagation is moving away from the stimulation
row of electrodes.

C.

Arrhythmic Prone Site Detection
As seen in Fig. 7 (A and B) there are no regions within the 9x9 mapping electrodes for

the two porcine samples that display CV speeds that are considered abnormal. To verify the
identification method of abnormal CV sites, activation times for a particular region within the
9x9 window were manually altered to slow the CV. Fig. 8 demonstrations a complete user
interface display of activation time contour plot, CV vector field, CV contour plot, as well as the
arrhythmic prone identification display.
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A)

B)

Fig. 7. (A) Contour plot of calculated CV in m/s from Fig. 6 activation times sample data.
(B) Arrhythmic prone site identification plot. From the calculated CV speeds in Fig. 7 A. there
are no abnormally slow CV speeds detected in the data, and green, indicating normal CV,
appears at all locations.
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Fig. 8. Complete MATLAB interface after data is processed. This particular set of activation time
data has been manipulated to slow CV speeds in the upper left hand portion of the 9x9 array.
There are no vectors that appear in the upper left portion of the CV vector field due to their small
magnitude. This was done in order to verify ability of the program to calculate and identify CV
speeds of less than 0.08 m/s as “Arrhythmic Prone”. The red area that is identified in the
“Arrhythmic Prone” site identification panel is displayed by a mechanism created in MATLAB
that displays any CV speeds less than 0.08 m/s as red. Any CV calculated above 0.08 m/s is
displayed in green.
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Fig. 9. Complete MATLAB interface of data that possesses two major arrhythmic prone sites
based on CV speeds less than 0.08 m/s. Individual electrode activation times were manipulated
in this data set to contain two areas that display abnormal CVs. There is consistency between all
four panels that allow for clear interpretation of the “arrhythmic prone” sites.
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IV. Discussion
We have been able to design an inexpensive electrode array that has the ability to study
the electrophysiological characteristics of isolated heart tissue. Due to recent efforts in the
development of engineered heart tissue patches as a potential treatment for myocardial infarction
repair, there is a need for a reliable way of determining the electrical properties of isolated
patches of cardiac tissue.
We have been able to develop an electrode array complete with a data acquisition and
analysis program that is able to detect changes in electrical potential for individual electrodes.
Mechanisms within the analysis program have the abilities to send a desired current input
through selected electrodes, record the electric potential changes in the cardiac tissue sample,
and assign the appropriate activation time to the individual mapping electrodes. These activation
times are then translated into conduction velocities over the mapping portion of the electrode
array. Finally, the program is able to identify areas within the mapping window that displays CVs
that would allow a reentrant circuit to develop.
The system was verified using porcine tissue samples that were placed in a controlled
tissue bath system that maintained normal physiological conditions. The system has the ability
to control temperature, pH, and the circulation of the medium using a feedback control system.
The protocol for determining activation threshold is common among literature in cardiac
mapping. Tissue is stimulated with an electrical current and is continually increased until an
active response is achieved in the tissue sample (29, 31, 41). We followed the correct procedure
for finding activation threshold but were unable to achieve tissue activation in the porcine
samples. We believe this is due to the limited porcine tissue trials. We were able to verify that
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that current stimulation portion of the LabVIEW allows the user the ability to change current
amplitude, pulse width, and frequency.
Conduction velocity is calculated using the same method performed by Bayly et al. [36]
and described in Methods section (II.D). This provides real-time visual feedback on the
magnitude and speed of electrical propagation, and is used to indicate potential arrhythmic prone
regions. There are other methods that only measure the magnitude of CV across the tissue. The
visualization of the vector field enhances the ability of our system to also show the direction of
electrical propagation. Future work would allow the direction of vector fields to also play a part
in the identification of an arrhythmic prone site.
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V. Recommendations, Limitations, Future work
One of our objectives was to expand and update previous efforts within the lab for
electrical characterization of isolated cardiac tissue. We believe we have not only fulfilled this
objective but have opened up more avenues for future research, in our lab, to explore.

A.

Recommendations
The ability to maintain tissue sample stability within the tissue bath was not as effective

over a large range of tissue sample sizes. The porcine samples that we received varied greatly in
size due to variation in animal ages. This made securing the larger isolated samples difficult
using the current clamps in the tissue bath. We therefore recommend searching for an alternative
clamping mechanism that that easily adjusts for varying sizes of samples due to the wide age
range of samples we receive in the lab.
A bath tissue system upgrade is recommended, as the viability of the cardiac tissue is
essential in achieving accurate recordings. The tissue bath offers a great deal of control as far as
maintaining relevant physiological conditions is concerned. This is accomplished by having
multiple tubes, electrodes, meters, and wires being placed into the tissue bath. This causes an
issue when trying to maneuver the electrode array to various regions of the tissue where multiple
controlling components need to be held into the DMEMs solution. We suggest updating the
acrylic chamber with permanent clamps to secure the various controller components in the tissue
bath to enable more room for the experimenter to operate.
Currently, the “arrhythmic prone” identification mechanism is only taking CV magnitude
into consideration for identifying areas that display abnormal CV. Based on literature a CV speed
less that 0.08 m/s is considered abnormal. This is not the only property that can cause a reentrant
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circuit. A mechanism that also characterizes the angle differences in sequential CV vectors may
be useful in determining areas that may still display arrhythmic prone traits but display normal
CV speeds.

B.

Limitations
As previously mentioned, the number of porcine samples available to study limited our

ability to be successful in observing tissue activation in our porcine sample studies. Because of
this limitation we were unable to verify the cardiac tissue mapping electrode array to determine
pro-arrhythmic tissue substrates using a single porcine sample. Nonetheless, we verified the
electrode array by importing previously recorded data and simulating different conduction
scenarios. Further studies in porcine or small animals tissues such as rat or guinea pig should be
performed.
The number of mapping electrodes is limited by the number of available slots in the
individual modules that are compatible with MATLAB. The 9x9-mapping surface is smaller than
previous work done in the lab that used an 11x11-mapping surface. There are 144 available slots
for electrodes in the current DAQ system. If the mapping surface is needed to be larger than
12x12 alternative methods must be used.
Finally, another significant limitation was the rigidity of the electrode array itself. We are
trying to map using a flat surfaced electrode array on a curved surface of cardiac tissue. Slight
pressure is necessary to maintain sufficient contact for all electrodes in the array. The design of a
flexible electrode array may be able to alleviate this issue.

27

C.

Future Work
This study has provided a significant upgrade within the lab for the mapping system for

electrical properties in isolated cardiac tissue. The device that has been developed is intended for
further cardiac mapping efforts within the lab as well as in the development and research of
engineered cardiac tissue patches. These patches have been characterized mechanically [43]; the
next progression before in-vivo animal models is to characterize the patches electrically.
The recent upgrades to the mapping system as well as previous efforts in the lab that have
provided adequate baseline electrophysiological activity for both porcine and rats that will allow
for a wide range of future cardiac mapping research.
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VI. Conclusions
Advances in our understanding in both biomaterials and cellular scaffolds have opened
up many novel approaches in resolving medical diseases we have today. Ex vivo characterization
of these prospective approaches serve as a valuable platform for predicting the scaffold potential
viability as a solution to manage myocardial infarction.
The system we have developed offers a portable and accessible option for ex-vivo
electrical characterization of isolated cardiac tissue. The primary limitation in ex-vivo
characterization of cardiac tissue is the time to analyze a particular recording; the programming
allows for real time analysis instead of extensive offline efforts. This system has the ability to
analyze the activation times of 81 mapping electrodes, calculate CV vector fields, display CV
contour plots, and identify areas within the mapping window that display CV speeds that are
considered “arrhythmic prone”. This system coupled with a formerly developed tissue bath
system [29] allows for characterization of cardiac tissue from both rats and piglets in
physiologically relevant conditions.
Results from this study will provide a foundation for future research in which arrhythmic
prone sites are characterized and identified on isolated cardiac tissue/ engineered cardiac patches.
The ex-vivo recognition of arrhythmic prone sites will serve as a valuable tool when determining
if implanting engineered heart tissue patches are a rational solution to myocardial infarction.
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APPENDICES
A. List of abbreviations
CHD: coronary heart disease
ICD: Implantable cardioverter-defibrillator
EHT: Engineered heart tissue
CV: conduction velocity
ECG: electrocardiogram
MI: myocardial infarction
DMEM: Dulbecco's Modified Eagle's Medium
VI: Virtual instrument
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B. Protocol for isolated porcine heart tissue mapping.
Date: ____________________ Weight (grams): ___________ Piglet number: ______________
Time of death: _____________
1) Prepare medium and saline in warm bath (room 316) and wait for them to reach 37°C.
2) Prepare bath close to mapping system with warm water, and connect necessary cables.
3) Pick up heart from Dr. Buddington, psychology building. Place in ice and transport to
Engineering Technology Building.
4) Prepare bath with warmed DMEM, place temperature controller and turn on Hot plate and pH
Controller.
5) Rinse in warmed saline. Section LV tissue. Place in bath. Time: __________,
pH:____________, Temperature: ____________
6) After 5-10 min. Rare spontaneous beating, determine threshold value. Run 5 seconds pacing at
1 beat per second, Recording last 4s, start at 0.5 mA amplitude and increase by 0.1mA until
active response achieved.
Time:__________,Threshold value: _____________
7) Run two 5 seconds pacing episodes
Filenames: _____________ _______________
pH:__________, Temperature____________
8) Run two 10 seconds pacing episodes
Filenames: _____________ _______________
pH:__________, Temperature____________
9) Run two 20 seconds pacing episodes
Filenames: _____________ _______________
pH:__________, Temperature____________
10) Run two 60 seconds pacing episodes
Filenames: _____________ _______________
pH:__________, Temperature____________
11) Run two 300 seconds pacing episodes
Filenames: _____________ _______________
pH:__________, Temperature____________
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C. MATLAB program developed to obtain conduction velocity.
%Matlab code to obtain the conduction velocity vector fields and mean
%conduction velocities%
%Thomas Shannon Fall 2015-Spring 2016
clear all
%insert excel file with raw data%
data=xlsread('data.xls');
%maxt=maximum time%
%mint=minumum time%
maxt=max(data(:,3));
mint=min(data(:,3));
%countour data
contourx=data(:,1);
contoury=data(:,2);
contourz=data(:,3);
%The following Polynomial fitting work completed by Emanuel Villa and
%edited by Thomas Shannon
% create variable to calculate the length of the data LOD=length(data)%
LOD=length(data);
for i=1:LOD,
V=data(i,:);
count=0;clear window; clear window2;
for j=1:LOD,
if(abs(data(j,1)-V(1))<3 && abs (data(j,2)-V (2))<3 && abs(data(j,3)-V (3))<4)
count=count+1;
window(count,:)=data(j,:);
end
end
if length(window)>8
variance(i,1)=var(window(:,3));
av_keep=(window(:,3)>0);
Sums=sum(window(:,3).*av_keep);
countav=sum(av_keep);
average(i,1)=Sums./countav;
count2=0;
for k=1:length(window(:,1))
if window(k,3)>(0.3*average(i)) && window (k,3)<(1.7*average(i))
count2=count2+1;
window2(count2,:)=window(k,:);
%remake the array from window data%
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if exist('CT','var')
CT=[CT;window2(count2,:)];
else
CT(1,:)=window2(1,:);
end
end
end
modelterms=[2 0;0 2;1 1;1 0;0 1;0 0];
polymodel2=polyfitn(window2(:,1:2),window2(:,3),modelterms);
%polyfitn function downloaded from internet%
a=polymodel2.Coefficients(1);
b=polymodel2.Coefficients(2);
c=polymodel2.Coefficients(3);
d=polymodel2.Coefficients(4);
e=polymodel2.Coefficients(5);
f=polymodel2.Coefficients(6);
x=data(i,1);
y=data(i,2);
Tx=2*a*x+c*y+d;
Ty=2*b*y+c*x+e;
Vx(i,1)=Tx/(Tx*Tx+Ty*Ty);
Vy(i,1)=Ty/(Tx*Tx+Ty*Ty);
vel(i,:)=[x,y,Vx(i),Vy(i)];
mag(i,1)=sqrt(((Vx(i))^2)+((Vy(i))^2));
R2(i,1)=polymodel2.R2;
RMSE(i,1)=polymodel2.RMSE;
NRMSE(i,1)=polymodel2.RMSE/(maxt-mint);
Z(i,1)=a*data(i,1).^2+b*data(i,2).^2+c*data(i,1).*data(i,2)+d*data(i,1)+e.*data(i,2)+f;
resid(i,1)=abs(Z(i,1)-data(i,3));
if (R2(i)<0||abs(mag(i))>3||resid(i)>1||isnan(resid(i)))
velcorr(i,:)=[0,0,0,0];
mag(i,1)=0;
resid(i,1)=0;
R2(i,1)=0;
else
velcorr(i,:)=vel(i,:);
mag(i,1)=sqrt(((Vx(i))^2)+((Vy(i))^2));
resid(i,1)=abs(Z(i,1)-data(i,3));
R2(i,1)=polymodel2.R2;
end
end
count=0;
end
X=velcorr(:,1); Y=velcorr(:,2); VX=velcorr(:,3); VY=velcorr(:,4);
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%Thomas Shannon
%Activation Time contour
AT=subplot(2,2,1)
xv = linspace(1, 9, 50);
yv = linspace(1, 9, 50);
[Xinterp,Yinterp] = meshgrid(xv,yv);
Zinterp = griddata(contourx,contoury,contourz,Xinterp,Yinterp);
contourf(Xinterp,Yinterp,Zinterp);
[c,h]=contourf(Xinterp,Yinterp,Zinterp, 10); clabel(c,h);
% Adds contour level labels on
grid on
colormap(AT,parula(10))
axis equal
title('Contour Plot of Activation times (ms)')
xlabel('X axis (0.635 mm spacing between electrodes)')
ylabel('Y axis')
%AT contour w/ CV vectors
CVV=subplot (2,2,2)
hold on
quiver(X,Y,VX,VY,1,'black')
hold off
grid on
axis equal
title('Conduction Velocity Vectors')
xlabel('X axis (0.635 mm spacing between electrodes)')
ylabel('Y axis')
%CV Contour
CV=subplot(2,2,3)%
VX=velcorr(:,3);
VY=velcorr(:,4);
AVX=abs(VX);
AVY=abs(VY);
AP=sqrt(AVX.^(2)+AVY.^(2));

%ABSOLUTE VELOCITY OF VECTORS

xx = linspace(1, 9, 50);
yy = linspace(1, 9, 50);
[Xinterp,Yinterp] = meshgrid(xx,yy);
AZinterp = griddata(X,Y,AP,Xinterp,Yinterp);
contourf(Xinterp,Yinterp,AZinterp);
[C,h]=contourf(Xinterp,Yinterp,AZinterp, 10); % Adds contour level labels on
v=[0.08];
clabel(C,h,'Font size',14,'Color','Red');
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% CV identified at 0.08 M/sec as Arryhthmic prone.
%Forces a contour if any CV values are found at 0.08 M/sec
% CV identified at 0.08 M/sec as Arryhthmic prone.
grid on
colormap(CV,summer(6))
axis equal
axis tight
xlabel('X axis (0.635 mm spacing between electrodes)')
ylabel('Y axis')
title('Contour plot of Conduction Velocities in (m/s)')
%"AP" indentifier
API=subplot(2,2,4)%
contourf(Xinterp,Yinterp,AZinterp, [min(AZinterp(:)); .08]);
colormap([1,0,0; 0,1,0])

grid on
axis equal
axis tight
xlabel('X axis (0.635 mm spacing between electrodes)')
ylabel('Y axis')
title('"Arrhythmic Prone" sites identified by slow CV')
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D.

Preliminary data using saline solution.

Prior to porcine experiments, bench tests were performed in saline solution to verify
current stimulation waveform through the peripheral row of electrodes as well as confirm
individual electrode recordings. For this experiment, the electrode array was suspended freely in
a beaker of saline solution. The following results verify we were able to deliver current through
the stimulation row of electrodes as well as record the voltage potential in the 81 mapping
electrodes seen in Fig. 10. In Fig. 11 we have our initial, or bench test, peak detector configured
to determine the stimulus artifact in saline solution. In porcine experiments, we changed the peak
detector criteria to determine tissue activation rather than stimulus artifact.

Fig. 10. Preliminary LABVIEW display showing voltage response to a single square wave
current pulse in saline solution for 81 mapping electrodes. The large deflection seen is the
stimulus artifact from the current pulse.
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Fig. 11. Peak times of 81 mapping electrode recordings in saline solution experiments. The table
represents the spatial location of the 9x9 array of electrodes. The peak detector was configured to
detect stimulus artifact and 70 out of the 81 recordings show peak time of 804-808 ms. This is
consistent with the time of the leading edge of the stimulus waveform in 70 recordings
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